Protagonist Logo. Click to navigate to a home page

Participate in Protagonist Clinical Trials

For information on clinical trials currently being conducted by Protagonist or our partners, including eligibility criteria and clinical site locations, please visit clinicaltrials.gov or contact
[email protected].

Drug Therapies in Clinical Studies

Rusfertide (PTG-300) is a hepcidin mimetic currently being studied as a treatment for polycythemia vera (PV).

Icotrokinra (JNJ-2113) is an oral peptide designed to block the IL-23 receptor, targeting inflammation in moderate-to-severe plaque psoriasis, ulcerative colitis, and other IL-23-mediated diseases.


Developed through a collaboration between Protagonist Therapeutics and Janssen Biotech (a Johnson & Johnson company), icotrokinra is in Phase 3 trials for psoriasis and psoriatic arthritis, and Phase 2b trials for ulcerative colitis. J&J retains exclusive global rights for its development and commercialization*.

 

*All icotrokinra trials conducted by J&J. Learn more.

Learn More about Our VERIFY Polycythemia Vera Clinical Study
LEARN MORE

Learn More About PV and the VERIFY Clinical Study

Protagonist Therapeutics Chief Medical Officer Dr. Arturo Molina joins Talk! with Audrey to discuss the VERIFY Phase 3 clinical study, along with the common symptoms and challenges faced by PV patients. Watch the full interview to learn more.

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.